Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 197 clinical trials
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. RO7425781 will be administered to participants with r/r MM for whom no standard-of-care treatment exists or who are intolerant to those established therapies. The study consists of two parts: dose-escalation of RO7425781 (Part 1) and a randomized …

refractory multiple myeloma
measurable disease
cancer
  • 5 views
  • 24 May, 2022
  • 9 locations
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)

The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone. People with multiple myeloma who have received …

refractory multiple myeloma
lenalidomide
dexamethasone
measurable disease
  • 0 views
  • 06 Jun, 2022
  • 12 locations
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)

drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated

proteasome inhibitor
measurable disease
monoclonal antibodies
tumor cells
monoclonal protein
  • 15 views
  • 24 May, 2022
  • 37 locations
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

An open-label, Phase 1/2 study of HPN217 as monotherapy to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma

platelet count
proteasome inhibitor
measurable disease
refractory multiple myeloma
neutrophil count
  • 35 views
  • 15 Mar, 2022
  • 14 locations
A Study of WVT078 in Patients With Multiple Myeloma (MM)

relapses and/or refractory Multiple Myeloma (MM)

refractory multiple myeloma
proteasome inhibitor
immunomodulatory imide drug
  • 28 views
  • 16 Jun, 2022
  • 13 locations
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

combination with bortezomib and dexamethasone. Around 40 adult participants with relapsed/refractory multiple myeloma will be enrolled at approximately 20 sites across the world. Participants will

bortezomib
dexamethasone
measurable disease
refractory multiple myeloma
cancer
  • 0 views
  • 15 May, 2022
  • 18 locations
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

bortezomib
dexamethasone
measurable disease
carfilzomib
refractory multiple myeloma
  • 0 views
  • 17 May, 2022
  • 42 locations
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3)

The purpose of this study is to compare the efficacy of teclistamab-daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).

lenalidomide
dexamethasone
measurable disease
bortezomib
progressive disease
  • 0 views
  • 03 Jun, 2022
  • 82 locations
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously

cell transplantation
dexamethasone
carfilzomib
bisphosphonate
daratumumab
  • 30 views
  • 28 Jun, 2022
  • 124 locations
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate

refractory multiple myeloma
dexamethasone
cancer
decitabine
  • 0 views
  • 12 May, 2022
  • 25 locations